Published in Br J Cancer on March 25, 2014
Correlation between the Uptake of 18F-Fluorodeoxyglucose (18F-FDG) and the Expression of Proliferation-Associated Antigen Ki-67 in Cancer Patients: A Meta-Analysis. PLoS One (2015) 0.89
Specific transport of 3-fluoro-l-α-methyl-tyrosine by LAT1 explains its specificity to malignant tumors in imaging. Cancer Sci (2016) 0.76
Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. Cancer Sci (2016) 0.75
Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET. EJNMMI Res (2017) 0.75
Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem (1998) 3.44
Characterization of 21 newly established esophageal cancer cell lines. Cancer (1992) 2.87
Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol (2000) 2.77
Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta (2001) 2.41
Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol (2004) 2.22
Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol (1999) 1.95
L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer (2006) 1.57
L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int (2009) 1.57
Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer (2008) 1.46
Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest (2007) 1.41
l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci (2008) 1.37
Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol (2010) 1.27
Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. Br J Cancer (2012) 1.23
High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int (2011) 1.22
Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer. Anticancer Res (2010) 1.20
Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol (2005) 1.17
LAT1 expression is closely associated with hypoxic markers and mTOR in resected non-small cell lung cancer. Am J Transl Res (2011) 1.16
Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis. Cancer Sci (2011) 1.11
Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res (2007) 1.07
Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract. Virchows Arch (2007) 1.05
Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET. J Nucl Med (2012) 1.02
¹⁸F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with ¹⁸F-FDG PET and immunohistochemistry. Ann Nucl Med (2010) 0.99
Synthesis of isomers of 18F-labelled amino acid radiopharmaceutical: position 2- and 3-L-18F-alpha-methyltyrosine using a separation and purification system. Nucl Med Commun (1997) 0.95
L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res (2011) 0.93
Establishment and characterization of mammalian cell lines stably expressing human L-type amino acid transporters. J Pharmacol Sci (2008) 0.93
Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma. Eur J Nucl Med Mol Imaging (2013) 0.86
Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma. J Nucl Med (1996) 0.85
18F alpha-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med (1999) 0.85
18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med (2009) 0.84
Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun (1999) 0.82
Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET. AJR Am J Roentgenol (2010) 0.81
18F-FAMT-PET is useful for the diagnosis of lymph node metastasis in operable esophageal squamous cell carcinoma. Ann Surg Oncol (2010) 0.81
¹⁸F-FAMT in patients with multiple myeloma: clinical utility compared to ¹⁸F-FDG. Ann Nucl Med (2012) 0.81